4//SEC Filing
LANGER DENNIS 4
Accession 0001104659-25-099782
CIK 0001671502other
Filed
Oct 14, 8:00 PM ET
Accepted
Oct 15, 5:15 PM ET
Size
16.2 KB
Accession
0001104659-25-099782
Insider Transaction Report
Form 4
LANGER DENNIS
Director
Transactions
- Purchase
ADSs
2025-10-14$8.49/sh+15,152$128,640→ 15,153 total - Purchase
Series I Warrants (Right to Buy)
2025-10-14+15,152→ 15,152 totalExercise: $10.31From: 2025-10-14→ ADS (15,152 underlying) - Purchase
Series K Warrants (Right to Buy)
2025-10-14+15,152→ 15,152 totalExercise: $12.38From: 2025-10-14→ ADS (15,152 underlying) - Purchase
Series H Warrants (Right to Buy)
2025-10-14+15,152→ 15,152 totalExercise: $9.07From: 2025-10-14→ ADS (15,152 underlying) - Purchase
Series J Warrants (Right to Buy)
2025-10-14+15,152→ 15,152 totalExercise: $12.38From: 2025-10-14→ ADS (15,152 underlying)
Footnotes (7)
- [F1]Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer.
- [F2]Each ADS purchased together with a Series H Warrant, a Series I Warrant, a Series J Warrant and a Series K Warrant to purchase one ADS in the Issuer's private placement which closed on October 14, 2025, at a combined price of $8.49. The Series H Warrants, Series I Warrants, Series J Warrants and Series K Warrants are collectively referred to as the "Warrants."
- [F3]The Warrants were exercisable immediately upon issuance, subject to a beneficial ownership cap.
- [F4]The Series H Warrants will expire on the earlier of (i) five (5) years from the Closing Date or (ii) 30 days after the Company's public announcement that the Company has received Type C meeting minutes from the FDA indicating openness to baseline-controlled pivotal studies for QRX003 for the treatment of Netherton Syndrome.
- [F5]The Series I Warrants will expire as follows: (i) 50% of the Series I Warrants will expire on the earlier of (A) five (5) years from the Closing Date or (B) 30 days after the Company's public announcement that the primary endpoint has been met in the monotherapy pivotal trial of QRX003 for the treatment of Netherton Syndrome, and (ii) 50% of the Series I Warrants will expire on the earlier of (A) five (5) years from the Closing Date or (B) 30 days after the Company's public announcement that the primary endpoint has been met in the adjuvant pivotal trial of QRX003 for the treatment of Netherton Syndrome.
- [F6]The Series J Warrants will expire on the earlier of (i) five (5) years from the Closing Date or (ii) 30 days after the public announcement of the receipt of either accelerated or traditional approval by the FDA of QRX003 for the treatment of Netherton Syndrome.
- [F7]The Series K Warrants will expire on the earlier of (i) five (5) years from the Closing Date or (ii) 30 days after the public announcement of the Company's sale of a Priority Review Voucher (PRV).
Documents
Issuer
Quoin Pharmaceuticals, Ltd.
CIK 0001671502
Entity typeother
Related Parties
1- filerCIK 0001274225
Filing Metadata
- Form type
- 4
- Filed
- Oct 14, 8:00 PM ET
- Accepted
- Oct 15, 5:15 PM ET
- Size
- 16.2 KB